Gilead Sciences Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (408)

Latest Posts

About This Stock More About This Stock
Here's What's Has Happened In The HCV Space Lately
Article By: Zacks Investment Research
Sunday, October 8, 2017 6:08 PM EDT
It is not a surprise that quite a few pharma and biotech companies are working on bringing new, improved, shorter-duration hepatitis C virus (HCV) treatments to the market. The market is thus getting crowded and seeing increased pricing pressure.
In this article: JNJ, GILD, ABBV, MRK Also: BMY
Week In Review: Another Billion Dollar Week For China Life Science Deals
Article By: ChinaBio® Today
Saturday, September 30, 2017 5:55 PM EDT
Shanghai Pharma Holding (SHA: 601607) may acquire part of Alvogen -- possibly Alvogen's US operations -- according to Bloomberg. Alvogen is a US-based generic drug maker thought to be worth as much as $4 billion.
In this article: NVO, SNY, SVA, AMGN, GILD, ZLAB, TSRO
Hot Options Report For End Of Day - Wednesday, September 13
Article By: The Options Insider
Wednesday, September 13, 2017 4:36 PM EDT
The most active equity options and strikes for end of the day Wednesday: AAPL, GILD and BAC.
In this article: AAPL, GILD, BAC
Biopharmaceuticals Portfolio In A Biotech Bull Market
Article By: Rod Raynovich
Tuesday, September 5, 2017 11:08 PM EDT
Biotech stocks broke through the July sector highs as tracked by major ETFs. However we are still about 25% off the July 2015 bubble highs but supported by good earnings fundamentals, strong technicals and potentially a seasonal strong Q4.
HH Biotech Bonanza: The Next Leg Up For Biotech Stocks
Article By: Tarun Chandra, CFA
Friday, September 1, 2017 8:05 PM EDT
The Biotechnology sector remains one of the top performing sectors this year with the benchmark Nasdaq Biotechnology Index of biotech stocks, as represented by the biotech ETF (IBB​), gaining 17% in the first half.
In this article: NVS, PFE, IBB, GILD, VRTX, XBI, XLV, ONCE, LABU


Latest Tweets for $GILD

No tweets yet!


Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Kurt Benson 3/24/2017 10:12:59 PM

I have to agree with your assessment on $GILD. Do you know anything about $VBIO? I read a promising article here about their having a major breakthrough in #Crohn's research.

Not a lot of info on the company though.

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Kirk Sheffield 3/24/2017 10:11:55 PM

I think $GILD will rebound. This isn't the only product they have in their pipeline.

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Alpha Stockman 3/24/2017 10:07:45 PM

I've been rather disappointed with #Gilead myself. After reading your article, I'm planning to offload some $GILD.

Gilead Sciences Receives Canadian Approval For HIV Drug
David Reynolds 2/20/2017 10:04:11 PM

The opening up of this market for #GileadSciences should bode well for the stock $GILD.

Gilead Sciences: Cheap Growth Or Value Trap?
Karen Klein 9/13/2016 5:39:48 PM

Excellent analysis, you have effectively convinced me to change my position on #Gilead. $GILD

3 Cult Stocks To Avoid In 2015
Bruce Powers 1/26/2015 8:01:06 AM

Great article and glad to read the reasoning to consider $GILD as a safer investment short, mid and long term.

3 Cult Stocks To Avoid In 2015
BreakingBad News 1/25/2015 6:09:51 PM

Sorry all, thanks for the clarification. My bad! Now that I've read it through, it all makes total sense. $GILD, $BAC, $WFM, and $VA are my plays for 2015.

3 Cult Stocks To Avoid In 2015
BreakingBad News 1/25/2015 4:48:08 PM

I'd say this is a minority view, I've seen several others stating that $GILD was a stock to buy this year.

1 to 8 of 8 comments